CILENGITIDE

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
26071
Cilengitide in subjects with newly diagnosed glioblastoma and methylated MGMT promoter gene- a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone (CENTRIC)

Back to Protocol section